The MES-CoBraD project completed its first year with a project meeting in Bucharest, Romania. After more than a year and a half, the project partners met face to face to discuss the project.
The main objective of MES-CoBraD is to improve diagnostic accuracy and therapeutic outcomes in people with Complex Brain Disorders (CoBraD): Neurocognitive (Dementia), Sleep, and Seizure (Epilepsy) disorders. For this purpose, the project is using data from multiple clinical and consumer sources through comprehensive, cost-efficient and fast protocols.
The European Research & Innovation project brings together internationally recognized experts in medicine, engineering, computer science, social health science, law, and marketing and communication from across Europe, a novel and demand-driven framework focused on improving the quality of life for patients, their caregivers, and the society at large. This powerful team of specialists combines clinical information and scientific research in CoBraD with technical innovation in secure data-sharing platforms, artificial intelligence algorithms, and expert systems of precision and personalized care.
In Bucharest, the partners shared their progress and experiences so far, reviewed the technical aspects of this promising and demanding project, and set the course for the second project year to come.
The main theme of last month’s meeting was the importance of Prospective Real-World Data Acquisition and the project’s scientific progress status. In this regard, the scientific partners will participate in a workshop where all the different scientific workgroups will present their work and progress so far.
As the team moves into the next phase of the project, the MES-CoBraD platform will begin to be implemented. This means that next year they will be able to announce how the use of the platform will affect the diagnosis and treatment of complex brain disorders.
Dr Christos Ntanos, the MES-CoBraD Project Coordinator from the Decision Support Systems Laboratory, National Technical University of Athens commented the following for the progress of the second project meeting:
“As the MES-CoBraD project enters its second year, we are affirming our shift from theory and planning to implementation and practice. We are looking ahead with excitement for the work ahead of us, and for pushing for meaningful preliminary tangible results across all objectives we have set out to achieve.”
Dr Elissaios Karageorgiou, our project’s Scientific Coordinator from the Neurological Institute of Athens, also commented on the ongoing project meeting:
“Steady progress presented across partners at the 2nd Progress Meeting and constructive discussions held in accelerating achievement of objectives and addressing questions and hurdles.”
Laurentiu Dragomir, PM of the team from SIMAVI, said that “Our primary focus with this project is to improve the quality of life of patients, their caregivers, and the society at large. And the implementation of the platform, which is our responsibility, will be a strong step towards this goal.”
As a main technology provider, SIMAVI is engaged in all the project stages: analysis of users’ requirements, design, development, testing, implementation, integration, end-users training and technical assistance. SIMAVI will provide its proven expertise in integration and eHealth AI-based solution development for patient monitoring.
We have teamed up with the National Technical University of Athens, from Greece, with the Neurological Institute of Athens (Greece), Fundació privada Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau (IR-HSCSP), VRIJE UNIVERSITEIT BRUSSEL (Belgium), UPPSALA UNIVERSITY (Sweden), Clalit Health Services- Rabin Medical Center Cognitive Neurology and Epilepsy Clinics (Israel), King’s College London (United Kingdom), HOLISTIC P.C. (Greece), STICHTING LIBER (Netherlands), Engineering - Ingegneria Informatica S.p.A. (Italy), MICHOPOULOS I. & CH. G.P. (Greece), University of Edinburgh (United Kingdom), CyberEthics Lab (Italy).
The MES-CoBraD project has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No 965422.
For more info: